Trial record 1 of 1 for:
nct04626674
A Gene Delivery Study to Evaluate the Safety of and Expression From SRP-9001 in Duchenne Muscular Dystrophy (DMD) (ENDEAVOR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04626674 |
|
Recruitment Status :
Recruiting
First Posted : November 12, 2020
Last Update Posted : December 24, 2020
|
Sponsor:
Sarepta Therapeutics, Inc.
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Sarepta Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an open-label gene delivery study evaluating the safety of and expression from SRP-9001 in individuals with Duchenne Muscular Dystrophy over 260 weeks. The primary endpoint is the change in quantity of micro-dystrophin protein expression from baseline to Week 12.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Muscular Dystrophy, Duchenne | Genetic: SRP-9001 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 10 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR) |
| Actual Study Start Date : | November 23, 2020 |
| Estimated Primary Completion Date : | May 31, 2021 |
| Estimated Study Completion Date : | December 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Duchenne and Becker muscular dystrophy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: SRP-9001
Patients will receive a single intravenous (IV) infusion of SRP-9001 on Day 1.
|
Genetic: SRP-9001
Single IV infusion of SRP-9001. |
Primary Outcome Measures :
- Part 1: Change From Baseline in Quantity of Micro-dystrophin Protein Expression Measured by Western Blot [ Time Frame: Baseline up to Week 12 ]
Secondary Outcome Measures :
- Vector Shedding as Measured by Polymerase Chain Reaction in Urine, Saliva and Stool Samples Post-infusion [ Time Frame: Baseline up to Week 260 ]
- Immunogenicity of SRP-9001 Determined by Level of Antibody Titers to rAAVrh74 [ Time Frame: Screening up to Week 260 ]
- Incidence of Treatment Emergent Adverse Events (TEAEs), Serious AEs and Adverse Events of Special Interest [ Time Frame: Baseline up to Week 260 ]
- Number of Participants with Clinically Significant Abnormalities in Vital Signs, Physical Examinations, Laboratory Parameters, Electrocardiograms (ECG) and Echocardiograms (ECHO) Findings [ Time Frame: Baseline up to Week 260 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 7 Years (Child) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Is male at birth, ambulatory and from 4 to under 8 years of age at time of randomization.
- Definitive diagnosis of Duchenne Muscular Dystrophy based on documented clinical findings and prior genetic testing
- Ability to cooperate with motor assessment testing.
- Stable dose equivalent of oral corticosteroids for at least 12 weeks.
- rAAVrh74 antibody titers are not elevated as per protocol-specified requirements.
Exclusion Criteria:
- Has a concomitant illness, autoimmune disease, chronic drug treatment, and/or cognitive delay/impairment that in the opinion of the Investigator creates unnecessary risks for gene transfer.
- Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
- Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
Other inclusion/exclusion criteria apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04626674
Contacts
| Contact: Medical Information | +1-800-690-2003 | clinicaltrials@sarepta.com |
Locations
| United States, California | |
| University of California, Davis | Recruiting |
| Sacramento, California, United States, 95616 | |
| Contact 916-734-3993 omsarwary@ucdavis.edu | |
| Principal Investigator: Craig McDonald, MD | |
| United States, Missouri | |
| Washington University in St. Louis | Recruiting |
| Saint Louis, Missouri, United States, 21205 | |
| Contact: Alyssa Sonsoucie 314-362-1566 sonsouciea@wustl.edu | |
| Principal Investigator: Craig Zaidman, MD | |
| United States, Ohio | |
| Nationwide Children's Hospital | Not yet recruiting |
| Columbus, Ohio, United States, 43205 | |
| Contact: Jerry Mendell | |
| Principal Investigator: Jerry Mendell | |
| United States, Virginia | |
| Children's Hospital of The King's Daughters | Recruiting |
| Norfolk, Virginia, United States, 23507 | |
| Contact: Cara Headrick 757-668-6417 Cara.Headrick@CHKD.ORG | |
| Principal Investigator: Crystal Proud, MD | |
Sponsors and Collaborators
Sarepta Therapeutics, Inc.
Roche Pharma AG
Investigators
| Study Director: | Medical Director | Sarepta Therapeutics, Inc. |
| Responsible Party: | Sarepta Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT04626674 |
| Other Study ID Numbers: |
SRP-9001-103 |
| First Posted: | November 12, 2020 Key Record Dates |
| Last Update Posted: | December 24, 2020 |
| Last Verified: | December 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Sarepta Therapeutics, Inc.:
|
Duchenne Muscular Dystrophy Gene-Delivery DMD |
Ambulatory Pediatric Micro-dystrophin |
Additional relevant MeSH terms:
|
Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Genetic Diseases, X-Linked |